Imaging tumor burden in the brain with 89Zr-transferrin

Journal of Nuclear Medicine

Volumn 54, Issue 1, 2013, Pages 90-95

  Evans, Michael J ^a   Holland, Jason P ^a   Rice, Samuel L ^a   Doran, Michael G ^a   Cheal, Sarah M ^a   Campos, Carl ^a   Carlin, Sean D ^a   Mellinghoff, Ingo K ^a   Sawyers, Charles L ^a   Lewis, Jason S ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

89Zr; Glioma; Molecular imaging; Positron emission tomography; Transferrin

Indexed keywords

FLUORODEOXYGLUCOSE F 18; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG; ZIRCONIUM TRANSFERRIN ZR 89;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD BRAIN BARRIER; CONTROLLED STUDY; DIAGNOSTIC IMAGING; DRUG DISTRIBUTION; DRUG UPTAKE; GLIOBLASTOMA; IN VIVO STUDY; ISOTOPE LABELING; MALE; MOUSE; NEUROIMAGING; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; TUMOR DIAGNOSIS; TUMOR LOCALIZATION;

ANIMALS; BRAIN NEOPLASMS; CELL LINE, TUMOR; DIAGNOSTIC IMAGING; FLUORODEOXYGLUCOSE F18; GLIOBLASTOMA; HUMANS; MALE; MICE; MICE, INBRED ICR; RADIOISOTOPES; TRANSFERRIN; TUMOR BURDEN; ZIRCONIUM;

EID: 84872011911     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.112.109777     Document Type: Article

References (25)

1. Bucci MK, Maity A, Janss AJ, et al. Near complete surgical resection predicts a favorable outcome in pediatric patients with nonbrainstem, malignant gliomas: results from a single center in the magnetic resonance imaging era. Cancer. 2004;101:817-824.
2. Stupp R, Hegi ME, van den Bent MJ, et al. Changing paradigms: an update on the multidisciplinary management of malignant glioma. Oncologist. 2006;11:165-180.
3. Denora N, Trapani A, Laquintana V, Lopedota A, Trapani G. Recent advances in medicinal chemistry and pharmaceutical technology: strategies for drug delivery to the brain. Curr Top Med Chem. 2009;9:182-196.
4. Waldman AD, Jackson A, Price SJ, et al. Quantitative imaging biomarkers in neuro-oncology. Nat Rev Clin Oncol. 2009;6:445-454.
5. la Fougère C, Suchorska B, Bartenstein P, Kreth FW, Tonn JC. Molecular imaging of gliomas with PET: opportunities and limitations. Neuro-oncol. 2011;13:806-819.
6. 89Zr-transferrin. Nat Med. 2012;18:1586-1591.
7. Calzolari A, Oliviero I, Deaglio S, et al. Transferrin receptor 2 is frequently expressed in human cancer cell lines. Blood Cells Mol Dis. 2007;39:82-91.
8. Recht L, Torres CO, Smith TW, Raso V, Griffin TW. Transferrin receptor in normal and neoplastic brain tissue: implications for brain-tumor immunotherapy. J Neurosurg. 1990;72:941-945.
9. Eavarone DA, Yu X, Bellamkonda RV. Targeted drug delivery to C6 glioma by transferrin-coupled liposomes. J Biomed Mater Res. 2000;51:10-14.
10. Weaver M, Laske DW. Transferrin receptor ligand-targeted toxin conjugate (Tf-CRM107) for therapy of malignant gliomas. J Neurooncol. 2003;65:3-13.
11. Cimini A, Mei S, Benedetti E, et al. Distinct cellular responses induced by saporin and a transferrin-saporin conjugate in two different human glioblastoma cell lines. J Cell Physiol. 2012;227:939-951.
12. Yoon DJ, Kwan BH, Chao FC, et al. Intratumoral therapy of glioblastoma multiforme using genetically engineered transferrin for drug delivery. Cancer Res. 2010;70:4520-4527.
13. 89Zr-DFO-J591 for immunoPET of prostate-specific membrane antigen expression in vivo. J Nucl Med. 2010;51:1293-1300.
14. 89Zr-7E11 immuno-PET. J Nucl Med. 2011;52:1608-1615.
15. Holland JP, Sheh Y, Lewis JS. Standardized methods for the production of high specific-activity zirconium-89. Nucl Med Biol. 2009;36:729-739.
16. Holland JP, Caldas-Lopes E, Divilov V, et al. Measuring the pharmacodynamic effects of a novel Hsp90 inhibitor on HER2/neu expression in mice using Zr-DFO-trastuzumab. PLoS ONE. 2010;5:e8859.
17. Ulmert D, Evans MJ, Holland JP, et al. Imaging androgen receptor signaling with a radiotracer targeting free prostate-specific antigen. Cancer Discov. 2012;2:320-327.
18. Evans MJ, Smith-Jones PM, Wongvipat J, et al. Noninvasive measurement of androgen receptor signaling with a positron-emitting radiopharmaceutical that targets prostate-specific membrane antigen. Proc Natl Acad Sci USA. 2011;108:9578-9582.
19. Galvez T, Teruel MN, Heo WD, et al. siRNA screen of the human signaling proteome identifies the PtdIns(3,4,5)P3-mTOR signaling pathway as a primary regulator of transferrin uptake. Genome Biol. 2007;8:R142-R153.
20. O'Donnell KA, Yu D, Zeller KI, et al. Activation of transferrin receptor 1 by c-Myc enhances cellular proliferation and tumorigenesis. Mol Cell Biol. 2006;26:2373-2386.
21. Koul D. PTEN signaling pathways in glioblastoma. Cancer Biol Ther. 2008;7:1321-1325.
22. Larson SM. Mechanisms of localization of gallium-67 in tumors. Semin Nucl Med. 1978;8:193-203.
23. 67Ga brain SPECT in patients with suspected central nervous system lymphoma or germinoma: clinical and economic value. Ann Nucl Med. 2003;17:359-367.
24. Mellinghoff IK, Schultz N, Mischel PS, Cloughesy TF. Will kinase inhibitors make it as glioblastoma drugs? Curr Top Microbiol Immunol. October 21, 2011 [Epub ahead of print].
25. Laske DW, Youle RJ, Oldfield EH. Tumor regression with regional distribution of the targeted toxin TF-CRM107 in patients with malignant brain tumors. Nat Med. 1997;3:1362-1368.